Contents

[Green Hill Canarias – Strategic Business Plan (2025 Update) 1](#_Toc204856638)

[🧭 Executive Summary 1](#_Toc204856639)

[🔒 Risk Analysis & Mitigation 4](#_Toc204856640)

# Green Hill Canarias – Strategic Business Plan (2025 Update)

**🧭 Executive Summary**

**🌱 Overview**

Green Hill Canarias represents a new chapter in European medicinal cannabis. Based in the Canary Islands, this vertically integrated venture is built on solid regulatory and fiscal foundations—benefiting from Spain’s progressive cannabis legislation and the Canary Islands Special Zone (ZEC)—while also drawing strength from a unique geographic location. Nestled in the heart of the Atlantic, the site enjoys some of the cleanest air in Europe, making it an ideal environment for pharmaceutical-grade cultivation. (see Company Description → Legal Structure & Location)

The subtropical climate, with high solar exposure and year-round temperature stability, enables energy-efficient operations (including solar-assisted infrastructure). Every aspect of the facility is designed for excellence: active positive-pressure systems with HEPA filters ensure cleanroom-grade air in cultivation zones, while processing areas follow EU-GMP-compliant pressure cascade protocols to maintain sterility and product integrity.

Green Hill is poised to bring to market the first EU-GMP-certified “live dried” cannabis flower in Europe. By employing precision freeze-drying technology (see Operations → Post-Harvest (Freeze-Drying)) to package product within ~48 hours of harvest, we retain the full terpene and cannabinoid profile while guaranteeing microbiological safety. This approach yields a pharmaceutical-grade flower of exceptional integrity—reliable, consistent, and ready to serve patients across regulated European markets from day one.

**🎯 Vision & Mission**

As the technological disruption tide peaks and a sweeping regulatory wave reshapes the global cannabis landscape, Green Hill is not born with a vision or a mission but with a destiny. We are here to harness this moment of harmonic convergence between innovation and reform, transforming a once-forbidden plant into a trusted therapeutic solution. Empowered by the superior state awareness made possible through machine learning, we’ve embedded our operational DNA into a living, adaptive business system—one that senses, learns, and improves in real time. Rooted in the pristine natural advantages of the Canary Islands—where solar abundance meets pharmaceutical-grade air purity—Green Hill anchors its innovation in a physical environment as optimized as its systems. Our facility is not just built on an island; it is embedded in an ecosystem that mirrors the harmony and precision of our operational model.

We envision Green Hill as a catalytic force for setting a new standard in cannabinoid-based therapeutics—where technology, ecology, and compliance converge. Our mission is not only to cultivate high-grade medicinal cannabis but to do so with deep respect for regulatory integrity, patient well-being, and systemic transparency. Every action we take—from GMP-certified cultivation to freeze-dried post-harvest—flows from a commitment to traceability, adaptability, and sustained excellence.

Through strategic foresight, collaborative alliances, and AI-driven agility, Green Hill is not simply entering the next era of cannabinoid-based medicine—we are composing its rhythm. We bring an orchestration of science, ethics, and environmental awareness that positions us to define the future of therapeutic cannabis across Europe..

**🛠️ Milestones Achieved**

Green Hill’s progress reflects a deliberately phased execution strategy rooted in regulatory foresight and operational agility. The project began with the formal establishment of its legal, fiscal, and technical foundation—including corporate registration, ZEC certification, a robust shareholder governance framework, and the full architectural and engineering design package—completed between 2024 and 2025.

The subsequent 18-month construction permit delay was turned into a high-leverage window for strategic innovation. During this period, the Green Hill team re-engineered the company’s operating model around AI-native systems, digitized workflows, and GMP-aligned documentation. As part of this evolution, Phase I infrastructure was deployed: a 1,000 m² cultivation division was constructed with fertigation and electrical systems scaled for future expansion.

This cultivation zone has since functioned as a live pilot for the company’s Quality by Design (QbD) framework—gathering environmental data across seasonal conditions, simulating variable cultivation scenarios, and enabling refinement of crop protocols for maximum consistency and compliance. Simultaneously, Green Hill validated its proprietary freeze-drying platform: optimizing equipment scale, developing market-specific drying protocols (recipes), and demonstrating that its flower could meet diverse regulatory and consumer demands across Europe.

This milestone phase concludes with a fully operational pilot site, an AI-enhanced quality and validation system, and a proven technical foundation for accelerated EU-GMP certification and scalable commercialization.

**💶 Capital Requirements & Structure**

The financial framework for Green Hill was initially structured around a €5.8 million funding commitment as detailed in the Shareholders’ Agreement. Of this, €1.5 million was strategically deployed to establish the project’s regulatory, technical, operational foundations and the mentioned milestones. As the project matured and market dynamics evolved—including global supply chain constraints, increased input pricing, target market realignment, and persistent inflation across key regions—an additional €1.6 million was identified as necessary to fulfill the updated operational scope and reach GMP-certified readiness. This adjustment reflects both the external macroeconomic shifts impacting the medicinal cannabis value chain and Green Hill’s internal drive to maintain excellence, adaptability, and strategic momentum.

As of July 2025, while not all funds have been formally transferred to the company account due to the timing of construction permits, the full initial capital requirement has already been committed by shareholders. Contributions made prior to 31 December 2024 carry an 8% preferred return, which is being integrated into the relevant shareholder agreements where applicable. This balanced structure—combining equity and profit participation loans—continues to provide both stability and flexibility, reinforcing Green Hill’s strategic focus and investor alignment throughout the project’s evolution.

**🧬 Strategic Advantage**

Green Hill’s operational model reflects its distinct geographic and regulatory position, reinforced by a project architecture that was reimagined during a strategic delay as a next-generation, AI-enabled platform. The facility is located in a pristine Atlantic island environment with exceptionally low ambient pollution—an ideal setting for pharmaceutical-grade cultivation. The site benefits from year-round climate stability and high solar exposure, enhancing energy efficiency and strengthening our sustainability objectives.

Post-harvest processing is built around precision freeze-drying executed within 24 hours of harvest. This process not only preserves the full cannabinoid and terpene profile and ensures microbiological integrity, but also delivers vastly superior shelf life—helping eliminate revenue loss from expired inventory and extending market reach. These capabilities are a direct result of real-time testing, recipe development, and quality refinement conducted throughout the pilot phase.

Environmental control is ensured through active positive-pressure HEPA-filtered air systems in cultivation areas, and EU-GMP-compliant pressure cascade protocols in processing zones. These systems uphold regulatory sterility, minimize cross-contamination risk, and sustain consistent product performance.

From the outset, the entire operation has been engineered to meet EU-GMP and ISO 14644 standards, positioning Green Hill as a future-ready manufacturer and the first European producer to commercialize live dried cannabis flower at pharmaceutical-grade quality.

**📈 Investor Proposition**

The investment structure has been carefully designed to align incentives, reduce friction in governance, and accelerate decision-making within a quality-by-design, AI-enabled framework. Key provisions include investor-controlled board majority, supermajority veto rights on critical decisions, and a clear liquidation preference structure. Investors benefit from early PPL returns and hold pre-emptive rights in future rounds.

As the project advances toward full EU-GMP production, investors participate in a roadmap supported by validated processes, proven technical platforms, and a facility already tuned to meet evolving international quality standards. These protections and incentives are built into the Shareholders’ Agreement and align each investor's interest with the long-term performance and operational integrity of the business.

An eventual exit is envisioned via strategic acquisition or industry consolidation, targeting liquidity upon full commercialization. With its early mover advantage, compliance-driven architecture, and investor-aligned governance model, Green Hill represents a compelling opportunity to deploy capital into a transformative, high-growth sector.

**🔒 Risk Analysis & Mitigation**

Effective risk management is essential for maintaining product quality, regulatory compliance, and patient safety in pharmaceutical manufacturing. In line with international GMP guidelines, Green Hill applies a structured and evolving risk management system grounded in key industry practices, including elements from HACCP (Hazard Analysis and Critical Control Points) and Failure Mode and Effects Analysis (FMEA).

Risk management is central to Green Hill’s operational philosophy and Quality Management System (QMS). Our approach includes a phased implementation of industry-standard methods, beginning with a direct risk prioritization model and evolving toward full integration of structured methodologies like HACCP and FMEA. These methodologies are widely used in pharmaceutical manufacturing to systematically identify, evaluate, and control potential risks that could impact product quality or compliance.

Instead of applying a fully systematized HACCP model from the outset, we began with a direct and proactive method: identifying all possible points where a process could fail, estimating the severity and likelihood of each event, and classifying risks into high, medium, or low categories. For each risk level, corresponding control or mitigation strategies were proposed, with a focus on preventive action.

This foundational logic—detect, classify, and control—is embedded across Green Hill’s operations. As we transition to Phase II, the risk framework will expand to include formalized tools such as risk matrices, severity-probability scoring, and real-time monitoring dashboards. These tools will align Green Hill’s QMS with WHO Annex 7 and FDA expectations for advanced pharmaceutical risk control systems. Real-time tracking, periodic reassessment, and cross-functional risk reviews form the operational backbone of our mitigation system.

We describe below the current risk map and the key controls in place:

**🏛️ Regulatory Risk**

**Risk:** Delays in licensing approvals or evolving regulatory frameworks may impact the projected timeline to commercial operations. **Mitigation:** Green Hill applies a structured risk prioritization process, adapted from HACCP methodology, to identify and preempt regulatory bottlenecks. Early engagement with Qualipharma ensures our AEMPS dossier meets current and expected requirements. Our regulatory roadmap is built to exceed EU-GMP compliance, allowing margin for future tightening. A financial buffer and dynamic scheduling system, guided by real-time regulatory updates, provide flexibility to adjust without disrupting strategic targets.

**🌍 Market Risk**

**Risk:** Market saturation, slower-than-expected patient growth, or price volatility could reduce revenue. **Mitigation:** In alignment with our structured risk prioritization framework, market dynamics are continuously monitored using scenario-based forecasting tools. Conservative pricing is already embedded into the financial model. Green Hill’s focus on GMP-certified, high-quality product positions the company in a premium segment less sensitive to commoditization. Entry into Germany is anchored by an LOI, and our multi-market export plan prevents overexposure to a single geography. This diversified approach, informed by HACCP-style risk mapping, allows agile adaptation to shifts in demand or pricing.

**⚙️ Operational Risk**

**Risk:** Crop loss or equipment malfunction could delay output. **Mitigation:** Following the structured methodology outlined in our GMP-aligned risk model, we proactively identify and prioritize operational risks through hazard mapping and severity-frequency classification. To mitigate these risks, Green Hill has built redundancy into all critical systems—for example, deploying multiple freeze-dryers to maintain production continuity. HVAC systems are covered under preventive maintenance agreements with Valtria. Crop loss is minimized through strict SOPs, environmental controls, and crop insurance. Real-time monitoring and deviation reporting ensure that early indicators are detected and addressed before they impact output.

**🧪 Quality Risk**

**Risk:** Quality deviations or batch contamination could lead to regulatory consequences. **Mitigation:** Green Hill applies internal and external quality testing standards to all batches. The company’s risk classification model ensures that all quality-critical operations are subject to high-frequency controls. Freeze-drying reduces exposure to contamination, and real-time deviation reporting strengthens batch integrity. Corrective and preventive actions (CAPA) are managed through ERP and documented within the QMS.

**💰 Financing Risk**

**Risk:** Unforeseen delays or overruns could require additional financing. **Mitigation:** Green Hill integrates financial forecasting into its QMS risk profile. Capital was raised with built-in buffers, and all core vendor contracts (e.g., Valtria) are fixed-cost. The project is designed to remain operationally solvent under delayed revenue or 10–15% CAPEX overruns. Phased investor commitments and reserve financing are ready for deployment if needed.

**👤 Key Personnel Risk**

**Risk:** Loss of critical staff could impact execution. **Mitigation:** In line with Green Hill’s structured risk assessment approach, personnel-related risks are addressed through functional mapping, cross-training, and redundancy planning. SOPs are developed to preserve operational knowledge and continuity. External consultants remain available as temporary technical backups. Post-revenue incentive plans and board-monitored retention strategies ensure long-term talent stability, aligning human resources with GMP continuity and strategic resilience.

**📉 Reputational & Compliance Risk**

**Risk:** Product recalls or regulatory breaches could harm the company’s standing. **Mitigation:** In line with our structured risk assessment approach, Green Hill embeds GMP compliance and traceability into every level of the QMS. Each critical control point is monitored for early signs of deviation, with audit trails maintained across all systems. Product liability insurance, formal recall protocols, and routine internal and external audits are part of the preemptive safeguards. This approach supports both regulatory confidence and long-term brand integrity.

**✅ Risk Governance**

Risk analysis in GMP involves systematically identifying, evaluating, and controlling potential risks throughout the manufacturing process. Green Hill applies this philosophy through a dynamic and integrated Quality Management System, which incorporates:

* **Risk Assessment:** Identifying and analyzing hazards to ensure product safety, quality, and efficacy in accordance with EU-GMP.
* **Failure Mode and Effects Analysis (FMEA):** A structured methodology to assess potential failure points and rank their impact and likelihood.
* **Regulatory Compliance:** Ensuring alignment with international standards from AEMPS, WHO, and FDA.
* **Tools and Methods:** Risk matrices, severity/probability scoring, and critical control point mapping enable systematic evaluation and proactive intervention.
* Our risk control model evolves from a severity-probability matrix to a fully HACCP-aligned pharmaceutical QMS.
* GMP validation, deviation management (CAPA), and ERP-based documentation allow real-time risk tracking and quality decision-making.
* Quarterly risk reviews with Board oversight ensure continuous improvement and strategic alignment.
* Green Hill’s transformation of regulatory delay into operational improvement reflects its ability to turn risk into opportunity.

By embedding pharmaceutical-grade risk thinking at every operational level, Green Hill ensures long-term resilience, regulatory credibility, and product integrity.

**References (Endnotes):**

[1] Canary Islands Special Zone (ZEC) official overview – *4% corporate tax regime approved by EU, supporting investment in Canary Islands*.

[2] Original Resinator. *Freeze-drying vs. traditional curing – dry & cure cannabis in ~48 hours instead of weeks*[[1]](https://www.theoriginalresinator.com/blog/what-is-freeze-dried-cannabis/#:~:text=The%20drying%20method%20most%20growers,as%20little%20as%2048%20hours).

[3] European Medicines Agency – *Good Manufacturing Practice (GMP) requirements*: *“Any manufacturer of medicines intended for the EU market must comply with EU GMP no matter where they are located.”*.

[4] Consorcio de la Zona Especial Canaria – *Green Hill Canarias S.L. inscription in Official Register (ROEZEC), Resolution 10 Oct 2024*. *(Annex: INSCRIPCIÓN GREEN HILL EN ZEC, Exp. 38/23/0068)*.

[5] Green Hill Canarias Shareholders’ Agreement (SHA), 26 July 2024 – Clause 3.3.3: *8% annual interest on Profit Participation Loans for contributions by 31 Dec 2024*.

[6] Green Hill Canarias SHA 2024 – Clause 3.3.4: *Contributions after 2024 carry no fixed interest (to incentivize early investment).*.

[7] Green Hill Canarias SHA 2024 – Board Composition clauses (Sec. 5.x): *Investors (Class B) appoint 3 of 5 directors; Founders (Class A) can appoint up to 2 if each retains ≥5% equity.*.

[8] Green Hill Canarias SHA 2024 – Board Majority provision: *Investor-appointed directors form majority; one serves as Chairperson.*.

[9] Green Hill Canarias SHA 2024 – Supermajority/Veto clause: *≥66% shareholder approval required for issuing new shares, incurring significant debt, M&A, or altering rights.*.

[10] Green Hill Canarias SHA 2024 – Reserved Matters list: *Major decisions (detailed in SHA Schedule) subject to investor veto via supermajority requirement.*.

[11] Prohibition Partners – *German Cannabis Report 2024:* *German medical cannabis sales expected ~€420M in 2024, rising to >€1B by 2028*.

[12] Honeysuckle Magazine (2024) – *“Germany’s Medical Cannabis Boom”*: *By Dec 2024, prescriptions were up >1000% vs. Mar 2024 after reclassification of cannabis*.

[13] Honeysuckle Magazine – *Bloomwell “Cannabis-Barometer” report insights:* *End-2024, number of cannabis prescriptions issued was 1000% higher than March 2024, indicating surge in self-paying patients*.

[14] Prohibition Partners – *German imports Q2 2024:* *Medical cannabis imports reached 11,706 kg in Q2 2024, +44% QoQ, reflecting record demand*.

[15] Service-Public.fr (French Govt) – *Medical Cannabis Trial Extension:* *France extended its medical cannabis pilot program through March 2026 to ensure continuity of care*[[2]](file://file-7Pymp8fsFnhzvKw1KbxaB3#:~:text=continuity%20of%20patient%20care,hubs%2C%20leveraging%20favorable%20climates%20or).

[16] Business of Cannabis (EU) – *Switzerland adult-use*: *Switzerland could be Europe’s first fully legal adult-use market by 2026 (pilot projects underway)*.

[17] Business of Cannabis – *Swiss cannabis liberalization*: *(Same as [16] above – Swiss regulatory changes enabling broader access)*.

[18] Business of Cannabis – *Czech Republic exports*: *Czech Republic’s 2024 medical cannabis harvest ~4.66 tons, with >4.4 tons exported (mostly to Germany)*.

[19] Business of Cannabis – *Czech decriminalization path*: *Czech Republic moving to decriminalize adult use by 2026, medical exports already growing*.

[20] Prohibition Partners – *Cannabis in Europe Update (Feb 2025)*: *European medical cannabis market expected to ~5x from €2.6B in 2024 to ~€12.6B by 2033, ~18% CAGR, driven by new country programs and greater acceptance.* (Source: **Cannabis\_in\_Europe\_Update\_2\_Feb2025.pdf**, Prohibition Partners).

[21] Cannabis Industry Journal – *Q1 2018 EU Market Update:* *“Right now, the legal market is absolutely dominated by Canopy, Aurora, Aphria and Tilray along with Dutch Bedrocan.”* (Illustrating early market concentration by Canadian LPs)[[3]](https://cannabisindustryjournal.com/news_article/q1-european-cannabis-industry-update-report/#:~:text=another%20way%20,Tilray%20along%20with%20Dutch%20Bedrocan).

[22] Molecules (MDPI) 2022, 27(5), 1719 – *Post-Harvest Operations Review:* *Vacuum freeze-drying is the best method for drying medicinal Cannabis, retaining maximal active compounds and preventing microbial activity*.

[23] Qualipharma – *Regulatory Dossier Timeline:* *Green Hill’s regulatory consultants indicate AEMPS permit achievable by ~Aug 2025 given early dossier prep and engagement.* (Internal communication, 2024).

[24] Green Hill Internal Plan – *Licensing Schedule:* *Parallel submission strategy to accelerate AEMPS approval by Q3 2025.* (Project Gantt, Rev. Jan 2025).

[25] Green Hill Financial Model – *Contingency for Certification Delay:* *Plan includes cash buffer to Q4 2026, ensuring operations even if GMP certification slips a quarter.* (Financial Annex, 2025).

[26] EU Directive 2004/27/EC (Art. 56a) – *Medicinal product packaging:* *All medicine packages in the EU must include Braille labeling for product name and key info*[*[6]*](https://www.euroblind.org/newsletter/2022/march/en/security-and-safety-your-fingertips-braille-medicinal-products#:~:text=However%2C%20stemming%20from%20an%20EU,and%20touchable%20for%20Braille%20users)*.* (Braille requirement effective since 2005).

[27] EU Directive 2001/83/EC (Art. 63(1)) – *Multilingual Packaging:* *Permits use of multiple languages on labelling/leaflet, provided the same information appears in all languages*[*[7]*](https://assets.hpra.ie/data/docs/default-source/external-guidance-document/aut-g0034-guide-to-labels-and-leaflets-of-human-medicines-v25.pdf?sfvrsn=181b0802_11#:~:text=Directive%202001%2F83%2FEC%2C%20Article%2063,this%20is%20text%20captured%20within)*.* (CMDh Best Practice Guide on Multilingual Packaging, 2021).

[28] Valtria Engineering Memo (2024) – *Facility HVAC Design:* *Design includes pressure cascade (higher pressure in clean areas) and >20 air changes/hour in processing, per EU GMP Annex 1.* (Valtria Memo #5040-2411-764-MEM).

[29] WHO/EU GMP Guidelines – *Cleanroom Differentials:* *Maintain positive pressure in critical areas to keep contaminants out.* (GMP Manual, Part I, Sec. 3).

[30] EU GMP Annex 1 (rev 2022) – *Environmental Control:* *HEPA filtration and ISO 8 equivalent conditions required for non-sterile medicinal plant processing.* (Guidance on HVAC for GMP facilities).

[31] Valtria Memo 5040-2411-764-MEM-02.00 – *HVAC Commissioning Specs:* *Details on temperature (22–25°C), humidity (~50% RH) controls and redundant systems.* (Engineering design document, Oct 2024).

[32] Qualipharma QA Protocol (2025) – *Equipment Qualification:* *Plan for IQ/OQ/PQ of all critical equipment (freeze dryers, etc.) prior to process validation.* (Internal QA protocol GH-QA-001).

[33] EudraLex Vol. 4 – *GMP Inspections:* *AEMPS/EMA inspectors will verify production records, training, calibration, etc., during pre-approval inspection.* (EU GMP Guidelines, Chapter 5: Production, and Chapter 8: Complaints & Recalls).

[34] EMA Inspection Guide (2019) – *Pre-Approval Audit Focus:* *Inspectors examine facilities, equipment logs, QC data, and compliance with MA dossier commitments.* (EMA Pre-Approval Inspection Guidance)[[8]](file://file-7Pymp8fsFnhzvKw1KbxaB3#:~:text=%28EMA%29).

[35] Valtria Contract Quote (2024) – *HVAC & Cleanroom Turnkey Cost:* *Fixed-price contract covering design, supply, installation of cleanrooms and climate systems for ~€600k.* (Project Offer #VAL-2024-07, Valtria).

[36] Comparable Project Benchmark – *HVAC/Cleanroom costs:* *Similar EU-GMP cultivation facility (2023) reported ~€580k HVAC spend.* (Internal benchmark provided by investor).

[37] Equipment Vendor Catalog – *Freeze Dryer Unit:* *Cuddon 120kg-capacity freeze dryers priced at ~€180k each (2 units planned). Comes with validation package.* (Cuddon Industrial FD spec sheet, 2024).

[38] Vendor Quote – *Rosin Press:* *Trichome Dynamics 20-ton rosin press, €25k, modular expansion possible.* (Supplier: Trichome Dynamics, Quotation #TD-2025-03).

[39] Agilent Technologies – *HPLC/GC Package:* *Analytical lab setup (HPLC-UV, GC-FID, consumables) ~€120k.* (Agilent Quote, Mar 2025).

[40] Fisher Scientific – *QC Lab Equipment:* *Microbiological incubator, analytical balance, etc., ~€30k.* (Catalog pricing 2025).

[41] Valtria Agreement – *Engineering Services:* *Design & project management fees €100k (included in CAPEX).* (Valtria Service Contract, 2024).

[42] Qualipharma Contract – *Regulatory Consulting:* *Licensing and GMP compliance support package €50k.* (Qualipharma Proposal, 2024).

[43] Green Hill SHA 2024 – *Liquidation Preference:* *Investors’ PPL + interest is returned first upon exit (equivalent to 1x liquidation pref with accrued coupon).* (SHA Section 7.2).

[44] Green Hill SHA 2024 – *Waterfall Distribution:* *After PPL principal+interest, remaining proceeds split by equity %. Mirrors typical VC preferred stock payout structure.* (SHA Schedule 3).

[45] Spanish Corporate Law (LSC) – *Majority Requirements:* *Art. 199: For S.L., bylaws may require up to 2/3 majority for significant decisions.* (Ley de Sociedades de Capital, Artículo 199).

[46] Green Hill SHA 2024 – *Pre-Emption Rights:* *Investors have rights to maintain their pro-rata in any new issuance, including via debt conversion.* (SHA Section 6).

[47] Green Hill SHA 2024 – *Anti-Dilution/Option to Contribute:* *Existing shareholders can contribute additional capital to prevent dilution if new funding is needed.* (SHA Section 6.4).

[48] Green Hill SHA 2024 – *Lock-up Period:* *No share transfers without consent during first 3 years.* (SHA Section 8.1).

[49] Green Hill SHA 2024 – *Permitted Transfers:* *Any new shareholder must adhere to SHA and PPL terms (Deed of Adherence required).* (SHA Section 8.3).

[50] Green Hill Canarias – *Financial Model (2025)*: Detailed projections of P&L, balance sheet, cash flow available in Annex; confirms viability under various scenarios.

[51] Green Hill Canarias – *Phase II Expansion Plan:* Outline for potential capacity doubling in 2029+ if market conditions warrant (not included in base case, but strategic optionality maintained).

[[1]](https://www.theoriginalresinator.com/blog/what-is-freeze-dried-cannabis/" \l ":~:text=The%20drying%20method%20most%20growers,as%20little%20as%2048%20hours) Guide to Freeze Dried Cannabis & Why It's the Future

<https://www.theoriginalresinator.com/blog/what-is-freeze-dried-cannabis/>

[[2]](file://file-7Pymp8fsFnhzvKw1KbxaB3#:~:text=continuity%20of%20patient%20care,hubs%2C%20leveraging%20favorable%20climates%20or) [[4]](file://file-7Pymp8fsFnhzvKw1KbxaB3#:~:text=AEMPS%20cultivation%2Fmanufacturing%20permit%20by%20August,for%20scheduling%20a%20GMP%20inspection) [[5]](file://file-7Pymp8fsFnhzvKw1KbxaB3#:~:text=delay%20in%20certification,for%20the%20medical%20cannabis%20market) [[8]](file://file-7Pymp8fsFnhzvKw1KbxaB3#:~:text=%28EMA%29) Green Hill Canarias – Strategic Business Plan (2025 Update) (5).docx

<file://file-7Pymp8fsFnhzvKw1KbxaB3>

[[3]](https://cannabisindustryjournal.com/news_article/q1-european-cannabis-industry-update-report/#:~:text=another%20way%20,Tilray%20along%20with%20Dutch%20Bedrocan) Q1 European Cannabis Industry Update Report - Cannabis Industry Journal

<https://cannabisindustryjournal.com/news_article/q1-european-cannabis-industry-update-report/>

[[6]](https://www.euroblind.org/newsletter/2022/march/en/security-and-safety-your-fingertips-braille-medicinal-products#:~:text=However%2C%20stemming%20from%20an%20EU,and%20touchable%20for%20Braille%20users) Security and safety at your fingertips, Braille on medicinal products | European Blind Union

<https://www.euroblind.org/newsletter/2022/march/en/security-and-safety-your-fingertips-braille-medicinal-products>

[[7]](https://assets.hpra.ie/data/docs/default-source/external-guidance-document/aut-g0034-guide-to-labels-and-leaflets-of-human-medicines-v25.pdf?sfvrsn=181b0802_11#:~:text=Directive%202001%2F83%2FEC%2C%20Article%2063,this%20is%20text%20captured%20within) assets.hpra.ie

<https://assets.hpra.ie/data/docs/default-source/external-guidance-document/aut-g0034-guide-to-labels-and-leaflets-of-human-medicines-v25.pdf?sfvrsn=181b0802_11>

Version ID: GHC\_STRATEGY\_V6\_FINAL — Executive Summary embedded and approved.